Melanoma Molecular Maps Projects


The IPD is a multicenter database, which gathers anonymized information about clinical and histopathological features as well as availability of biological material regarding patients with cutaneous melanoma enrolled by centers that participate in this project.
A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system).
Inspired to the principles of functional interactomics, this is a collection of schematic figures depicting the molecular pathways involved in cancer development and progression, with particular regard to melanoma. A close-to-hand visual guide to navigate in the ever-growing complexity of cancer molecular biology.

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

Cutaneous melanoma: A current overview.
Wick MR
Semin Diagn Pathol. 2016 Apr 16;():.
PMID: 27229301 [PubMed - as supplied by publisher]

Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations.
Gugger A, Barnhill RL, Seifert B, Dehler S, Moch H, Lugassy C, Marques-Maggio E, Rushing EJ, Mihic-Probst D
PLoS One. 2016;11(5):e0156115.
PMID: 27213536 [PubMed - in process]

Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients.
Berger AC, Davidson RS, Poitras JK, Chabra I, Hope R, Brackeen A, Johnson CE, Maetzold DJ, Middlebrook B, Oelschlager KM, Cook RW, Monzon F, Miller AR
Curr Med Res Opin. 2016 May 23;():1-23.
PMID: 27210115 [PubMed - as supplied by publisher]

The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year.
Damude S, Hoekstra-Weebers JE, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ
Ann Surg Oncol. 2016 May 18;():.
PMID: 27194552 [PubMed - as supplied by publisher]

Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.
Poukka M, Bykachev A, Siiskonen H, Tyynelä-Korhonen K, Auvinen P, Pasonen-Seppänen S, Sironen R
BMC Cancer. 2016 May 16;16():313.
PMID: 27184066 [PubMed - in process]

NCBI's Disclaimer and Copyright notice